| Assessment Status | Pre-submission consultation scheduled |
| HTA ID | 22066 |
| Drug | Axicabtagene ciloleucel |
| Brand | Yescarta® |
| Indication | For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 27/09/2022 |
| Rapid review completed | 10/11/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/11/2022 |
